TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combining LHu With Ultrasound Monitoring in IUI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing IUI treatments for:~  * Unexplained infertility (including endometriosis stage 1-2)~ * Mild male factor (\>5x106/ml motile sperm as determined by total sperm concentration x % A+B motility in the latest spermogram)~ * Donor insemination~* Natural or stimulated cycles with clomiphene citrate or letrozole~* At least 1 patent tube on hysterosalpingogram, hysterosonogram or laparoscopy within the last two years~* Antral follicular count ≥10 and FSH\<10~Exclusion Criteria:~* Polycystic ovarian syndrome or any cause of oligo or anovulation~* Patients taking other infertility medication (metformin, 17B estradiol, progesterone or gonadotropins)~* Presence of an ovarian cyst or a follicle \>20 mm on the first ultrasound or any reason for immediate HCG administration~* A previous sperm washing result with less than 5x106/ml motile sperm~* Previous inconclusive uLH test or inability to perform uLH testing

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- ultrasound alone group (Type: NO_INTERVENTION): Patients in the control group will have a standard ultrasound monitoring with HCG administered when the leading follicle reaches 18 mm, and IUI 36 h afterward.
- LH testing combined with ultrasound monitoring (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or over~* Able to read English~* Read, understood and signed the Informed Consent Form~* Agrees to participate and does not withdraw\\~* Either healthy (without diabetes) or has Type 1 or Type 2 diabetes~Exlcusion Criteria:~• Declines participation or withdraws before study completion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- No Treatment (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture - a Treatment for Children With Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed by pediatrician-~* Age-9-17 years~* Min. headache 8 times within the last month~Exclusion Criteria:~* Mentally illness~* Fear of needles

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Migraine_acupuncture and training (Type: EXPERIMENTAL): Migraine acupuncture and training
- Migraine training (Type: EXPERIMENTAL): Migraine training
- Tension_acupuncture and training (Type: EXPERIMENTAL): Tension headache acupuncture and training
- Tension headache training (Type: EXPERIMENTAL): Tension headache training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven stage IIIC ovarian epithelial cancer Chemosensitive to 6-8 courses of standard dose adjuvant chemotherapy (one regimen), such as cisplatin or carboplatin in combination with paclitaxel, or any other standard dose regimen Residual disease (no greater than 1 cm) following second look laparotomy Ineligible if no microscopic disease present following induction chemotherapy OR Histologically proven newly diagnosed stage IV ovarian epithelial cancer Achieved at least partial response (PR) (80% or greater reduction in tumor by CT scan) following six courses of standard dose chemotherapy (one regimen) OR Residual disease (no greater than 1 cm) or no disease determined at the time of second look laparotomy OR Histologically proven relapsed ovarian epithelial cancer Relapse following standard dose chemotherapy Chemosensitive Achieved at least PR after 4-6 courses of salvage chemotherapy (total of 2 regimens) No more than a six week interval between completion of standard dose chemotherapy and second look laparotomy~PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL ALT or AST no greater than 2.5 times normal Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: Ejection fraction at least 50% by MUGA scan No severe cardiac dysfunction or major heart disease No angina pectoris No ventricular dysrhythmias Essential hypertension allowed if controlled with medication(s) Pulmonary: DLCO at least 50% predicted No symptomatic obstructive or restrictive pulmonary disease Other: No active infections HIV negative No uncontrolled insulin dependent diabetes mellitus No uncompensated major thyroid or adrenal dysfunction No other malignancy within the past 5 years except nonmelanomatous skin cancer Not pregnant or nursing Negative pregnancy test~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No prior topotecan Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics Other: No concurrent nitroglycerin preparations or antiarrhythmic drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Booster Vaccination in Persons With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of clinically definite multiple sclerosis (CDMS) by the 2017 McDonald Criteria 38;~2. Age greater than or equal to 18 years;~3. Ability to travel to Griffin Hospital for phlebotomy and booster vaccination;~4. Completion of an initial COVID-19 vaccine series at least 4 weeks prior to booster randomization (i.e., two doses of either BNT162b2 or mRNA-1273, or one dose of Ad26.COV2.S);~5. Prior negative test for COVID-19 spike protein antibodies using a commercial assay;~6. Willing to undergo a booster vaccination with either BNT162b2, mRNA-1273 or Ad26.COV2.S.~Exclusion Criteria:~1. Inability to give consent;~2. Non-fluency in English;~3. Inability to adhere to the protocol;~4. Anticipated life expectancy of less than six months;~5. Lack of a primary care physician or treating neurologist;~6. Taking an immunosuppressive medication or chemotherapy for any other conditions aside fromMS;~7. Presence of another autoimmune condition requiring treatment;~8. Active treatment for cancer;~9. History of heavy alcohol use within the past year, as defined by the following criteria:~   1. Men: 5 or more alcoholic beverages per session or per day, or 15 or more per week;~  2. Women: 4 or more alcoholic beverages per session or per day, or 8 or more per week;~10. History of illicit drug abuse, e.g., cocaine, heroin, PCP, and/or narcotics within the past year;~11. Any condition that would jeopardize the safety or rights of the subject, make it unlikely for the subject to complete the study, or confound the study results.~12. Anaphylactic or other severe reaction to a previously administered COVID-19 vaccine;~13. MS relapse or worsening symptoms after initial COVID-19 vaccination.~14. Positive urine pregnancy test at screening \[women only\]. Test is waived in women who are post-menopausal or incapable of conception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Homologous booster vaccine group (Type: ACTIVE_COMPARATOR): A single dose booster of the same type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
- Heterologous booster vaccine group (Type: ACTIVE_COMPARATOR): A single dose booster of the opposite type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pain Management After Shoulder Prosthesis: A Clinical Trial of Nerve Block and Local Infiltration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* elective primary shoulder arthroplasty~Exclusion Criteria:~* reverse or delta prosthesis~* recent fracture near the shoulder~* allergic to amid-type local analgesics~* operation not under general anaesthesia~* incompetent, pregnant, below 18 or above 90 years old~* severe chronic neurogenic pain or sensory disturbances in the shoulder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Local infiltration analgesia (Type: EXPERIMENTAL): None
- Interscalene catheter (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: X-Ray Computed Tomography and Blood Reactive Oxygen Species Level

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants of health check program at our hospital who will receive a scheduled X-ray computed tomography examination for either lung (20 cases) or heart (20 cases).~Exclusion Criteria:~* Those whose age are under 50 or above 70 year-olds will be excluded.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Twenty subjects receiving health check program without X-ray computed tomography examination will be included as the control group.
- 2 (Type: None): Twenty subjects receiving health check program including X-ray computed tomography examination of lung will be included as the treatment group-1.
- 3 (Type: None): Twenty subjects receiving health check program including X-ray computed tomography examination of heart will be included as the treatment group-2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrollment and intervention with the investigational drug in Study PSIL201~Exclusion Criteria:~* Inability or unwillingness to complete study procedures, including regular completion of web surveys and telephone interviews with study personnel

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single-Dose of Psilocybin (Type: None): None
- Niacin-Control (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed Stage IIIB or IV non-resectable NSCLC. Recurrent disease after resection for earlier stage disease is acceptable as long as patients are at least 6 months from surgery.~* Treatment plan includes a platinum-based doublet chemotherapy.~* ECOG 0, 1 or 2.~* Self-reported loss of body weight or anorexia.~* Serum C-reactive protein ≥5 mg/L.~* Life expectancy of at least 6 months.~* Adequate bone marrow, liver and renal function.~* Normal serum potassium.~* Ability to comply with the study requirements and give written informed consent.~Exclusion Criteria:~* Known physical or functional obstruction of the gastrointestinal tract, malabsorption, intractable vomiting, uncontrollable diarrhea, concurrently receiving tube feeding or parenteral nutrition, or unable to swallow investigational drug product.~* Concomitant therapy with an appetite stimulant.~* History of poorly controlled hypertension or congestive heart failure.~* Any implanted devices that could interfere with DXA scanning.~* Prolongation of QT interval.~* History of additional risk factors for torsades de pointe.~* Concomitant therapy with beta-adrenergic receptor antagonists (beta-blockers) or ergot derivatives.~* Females who are breast feeding, pregnant or of child-bearing potential who are not using adequate birth control.~* Any second malignancy which might confound the interpretation of safety or efficacy assessments.~* Any condition which increases the patient's risk for participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study to Evaluate Safety of Nutriseal™ Nutriplace™ System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be \>21 years of age~2. Patients must require placement of a nasoenteral feeding tube~3. Patients have an endotracheal tube, OR Do not have an endotracheal tube but are sedated (RASS score of -2 or less) and/or obtunded (Glasgow Coma scale of 9-12)~4. Patients or legal authorized representative must be able to understand and adhere to all protocol procedures and be willing and able to provide written informed consent~Exclusion Criteria:~1. Patients must not have a history of:~   * Esophageal varices or ulcers~  * Upper airway obstruction~  * Upper GI stenosis or obstruction~  * Trauma involving sinuses, nares face or neck that would prevent Nasogastriv (NG) tube insertion~  * Deformities of the sinus cavities and/or skull base~  * Esophageal cancer or neoplasm~2. Patients must not have a significant concomitant illness that would adversely affect their participation in the study~3. Female patients who are pregnant or lactating

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nutriplace™ System (Type: EXPERIMENTAL): Placement of the Nutriseal™ Enteral Feeding Tube in the stomach or small intestine of adult patients who require feedings via the oro/nasoenteric route, using the Nutriplace™ System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Breast Density and the Role of Preoperative Mammography, Ultrasound, Elastography and MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:- Patients must have a suspicious breast lesion detected by a physical exam, mammography or U/S . that has not been surgically resected and is being considered to undergo biopsy if clinically indicated.~* Patients must be \>= 18 and \< 80 years of age, and female.~* Patients must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:- Patients who have already had primary surgical excision of the suspicious finding~* \<18 or \>80 years of age~* Pregnant or Lactating Women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Heart Association Stage B-D Heart failure due to ischemic, idiopathic or hypertensive causes, present for at least 3 months~* Left Ventricular Ejection Fraction ≤ 45 %~* Optimal medical therapy for heart failure~* No change in active cardiac medications for 2 weeks prior to randomization, beta-blockers must be started 3 months prior to randomization~* Sleep apnea with an AHI ≥ 15. Subjects with obstructive sleep apnea must also have an Epworth Sleepiness Scale score of ≤ 10 and no or mild daytime sleepiness~* Written informed consent~Exclusion Criteria:~* Heart failure due to primary valvular heart disease~* Presence of moderate to severe mitral insufficiency due to intrinsic mitral valve disease~* Hypertrophic obstructive or restrictive or post partum cardiomyopathy~* Exercise capacity limited by class IV angina pectoris~* Acute MI, cardiac surgery, PCI, AICD, or CRT within 3 months of randomization~* Active myocarditis~* Planned AICD or CRT~* Presence of a left-ventricular assist device~* Transplanted heart or expected to receive a transplanted heart within the next 6 months~* Pregnancy~* Current use of ASV or CPAP or mandibular advancement device for treatment of sleep apnea or treated with any investigational therapy during the last 4 weeks (including approved therapies being used in unapproved indications)~* A clinical history that would interfere with the objectives of this study or that would in the investigator's opinion preclude safe conclusion of the study~* Any other medical, social, or geographical factor, which would make it unlikely that the patient will comply with the study procedures (e.g. alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or history of non-compliance)~* Any contraindication to ASV therapy as detailed in the device provider manual

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard HF therapy (Type: NO_INTERVENTION): Subjects will receive optimal standard therapy for heart failure conforming to national guidelines as determined by the referring cardiologist
- Standard therapy for HF + ASV (Type: ACTIVE_COMPARATOR): Subjects will receive treatment with Adaptive Servo Ventilation in addition to optimal standard therapy for heart failure conforming to national guidelines, as determined by the referring cardiologist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing PCI/angiography~* No previously known side effects of statins~* Patients who sign an informed consent~* Age \> 18 years old~Exclusion Criteria:~* Patients with ST elevation myocardial infarction~* Patients with cardiogenic shock~* Patients with hypersensitivity to statins~* Patients with unexplained muscle pain~* Patients with acute liver disease~* Patients receiving cyclosporine, antifungal azoles, macrolide antibiotics, niacin, fibrates\> 1 quart grapefruit juice/day or nefazodone~* Patients with creatinine \> 2.0~* Patients with known malignancy~* Ejection Fraction \< 25%~* No coronary care unit patients~* No outpatients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues